unconjugated Estriol

Panels that include this biomarker

• Quad Screen 30294

  4 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Fri (Day shift); Report available: 4 days

  Method and collection

  Method

  Immunoassay (IA)

  Collection

  For manual orders use "Maternal Serum Screen Requisition" The Quad test in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Quad Screen test results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down Syndrome or Trisomy 18. The Maternal Serum Screen Requisition designed to obtain patient data and the patient's informed consent must be utilized when ordering the Quad Screen test. Because the Quad Screen test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient's diabetic status (is patient insulin dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.

  Reference notes

  See Laboratory Report

  Quest Diagnostics catalog page

  Compare

• Sequential Integrated Screen, Part 2 16133

  4 analytes · Serum · Fasting not stated

  Method and collection

  Method

  Chemiluminescence (CL) • Immunoassay (IA)

  Collection

  Collect between 14.0 to 22 6/7 weeks. Maternal date of birth (mm/dd/yy), Estimated Date of Delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results. Must complete patient demographic information using the Maternal Serum Screen Requisition.

  Reference notes

  See Laboratory Report

  Quest Diagnostics catalog page

  Compare

• Integrated Screen, Part 2 16150

  5 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Fri (a.m.); Report available: Tues-Fri, Mon p.m.

  Method and collection

  Method

  Chemiluminescence (CL) • Immunoassay (IA)

  Collection

  For manual orders use "Maternal Serum Screen Requisition". The Integrated Screen, Part 2 should be performed 14.0 weeks to 22.9 weeks gestational age. A special maternal serum screen requisition designed to obtain patient data and the patient's informed consent must be utilized when ordering this test. Because these results are influenced by certain patient characteristics, all data requested on the requisition form must be complete: Patient's (maternal) date of birth, estimated date of delivery, weight, race, diabetic status (is patient insulin dependent; prior to pregnancy), number of fetuses, repeat sample and neural tube defect history must be provided for interpretation of results.

  Reference notes

  See Laboratory Report

  Quest Diagnostics catalog page

  Compare

• Penta Screen 15934

  5 analytes · Serum · Fasting not stated · Turnaround Set up: Tues-Sat

  Method and collection

  Method

  Immunoassay (IA)

  Collection

  For manual orders use "Maternal Serum Screen Requisition". The Penta Screen test in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Penta Screen test results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down syndrome or Trisomy 18. The "Maternal Serum Screen Requisition" designed to obtain patient data and the patient's informed consent must be utilized when ordering the Penta Screen test. Because the Penta Screen test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient's diabetic status (is patient insulin-dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.

  Reference notes

  See Laboratory Report

  Quest Diagnostics catalog page

  Compare

• Serum Integrated Screen, Part 2 16167

  6 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Fri (a.m.); Report available: Tues-Fri, Mon p.m.

  Method and collection

  Method

  Chemiluminescence (CL) • Immunoassay (IA)

  Collection

  Collect between 14.0 weeks to 22 6/7 weeks. Maternal date of birth (mm/dd/yy), estimated date of delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results. Must complete patient demographic information using the Maternal Serum Screen Requisition.

  Quest Diagnostics catalog page

  Compare